Tristan Imbert co-opted as Independent Director

Core Viewpoint - EUROAPI announces the appointment of Tristan Imbert as Independent Director and Chair of the Audit Committee, following the resignation of Rodolfo Savitzky, effective January 1, 2026, subject to shareholder approval on May 27, 2026 [1][3]. Group 1: Leadership Changes - Rodolfo Savitzky resigns from his position as Independent Director effective December 31, 2025 [1]. - Tristan Imbert will be appointed as Independent Director and Chair of the Audit Committee, effective January 1, 2026 [1][3]. Group 2: Background of Tristan Imbert - Tristan Imbert has a diverse background in the pharmaceutical industry, starting his career in R&D at Sanofi Aventis in 1989 [2]. - He has held significant roles at Boston Consulting Group and Novartis, including Chief Financial Officer of Novartis Gene Therapies and Cimeio Therapeutics [2]. Group 3: Company Overview - EUROAPI focuses on reinventing active ingredient solutions, with approximately 200 products in its portfolio [4]. - The company operates five manufacturing sites in Europe and supplies customers in over 80 countries [5].